Conference Day 2

All agenda times are in EST. For PST, download the full event guide here.

8:00 am Coffee & Networking

8:45 am Chair’s Opening Remarks

  • John Rossi Senior Vice President Research CERo Research, Head of Translational Medicine, CERo Therapeutics

Harnessing Effective Tumor Models to Optimize Cell Therapy Development

9:00 am Leveraging Data from Tumor Animal Models to Translate Safe ErbB-Targeted Cell Therapies into the Clinic

Synopsis

  • Characterizing the best available models for the TME
  • Utilizing strategies to expand to models with better translatability
  • Advancing beyond animal models with the first clinical data for LEU-001

9:30 am Leveraging Orthotopic Tumor Xenograft Models to Develop iPSC-Derived Cell Therapies Against Glioblastoma Multiforme

  • Luis Borges Chief Scientific Officer, Century Therapeutics

Synopsis

  • Century’s iPSC NK and T cell platforms; harnessing the power of induced pluripotent stem cells to develop novel allogeneic cell therapies against multiple cancer types, including glioblastoma multiforme (GBM)
  • Introducing GBM clinical candidate selection using patient-derived cell xenografts implanted into the brain of recipient mice
  • Evaluation of the efficacy and local & systemic toxicities of CAR-iNK cells using orthotopic GBM-derived xenografts
  • Mimicking local tumor delivery of cell therapies by administering iPSCderived NK cells into the brain tumor lesion

10:00 am Morning Break & Poster Session

Harnessing Novel Constructs for Improved Dual Targeting

10:30 am Multiplex TALEN Gene-Editing for the Next Generation of CAR-T Cells in Solid Tumors

Synopsis

  • Gene editing allows expanding the success of allogeneic CAR-T therapies in hematological malignancies to solid tumors
  • Exploring various immune scenarios is needed depending on diseases/patient populations
  • TALEN®-mediated highly efficient complex engineering allows programming of these immune scenarios into allogeneic CAR-T cells to optimize persistence, potency, and safety

11:00 am The Promise of Combining CARs & NK Cells to Effectively Treat Solid Tumors

Synopsis

  • Outlining the multiple natural mechanisms for engaging tumors with natural killer T cells
  • Observing the mechanisms of tumor homing and persistence in mouse models and speculating the differential impact on solid tumors
  • Advancing CARs to enhance efficacy and targeting and exploring combinations with checkpoint antibodies

11:30 am Introducing Chimeric Engulfment Receptors CERs: Combining Classic CAR-T with Small Molecule Therapy to Improve Tumor Cell Clearance

  • John Rossi Senior Vice President Research CERo Research, Head of Translational Medicine, CERo Therapeutics

Synopsis

  • Characterizing CER T cells to enhance inducible target specific cellular damage, uptake and display of tumor antigens for removal of diseased cells
  • Discussing how this novel MOA may lead to a more durable response
  • Presenting non-clinical MOA data and future directions

12:00 pm Lunch & Networking

Leveraging Novel Engineering Approaches to Accelerate Clinical Development

1:00 pm Expert Panel: How Can We Utilize Gene Engineering to Scale Up and Scale Out?

Synopsis

  • Mapping out novel engineering techniques, such as in vivo editing, base editing, RNA editing etc.
  • Examining the pros and cons of novel approaches to inform future decision making
  • Assessing the impact of novel engineering approaches on producing standardized testing

1:30 pm Leveraging RNA to Produce More Controllable Cell Therapies

  • Daniel Getts Chief Executive Officer, Myeloid Therapeutics

Synopsis

  • Controlling drug exposure through the unique pharmacokinetics of RNA-based therapies
  • Impact of RNA-based cell therapies on minimizing manufacturing costs
  • Exploring methods to minimize immune attack on RNA therapies to enhance their therapeutic effect

2:00 pm Harnessing Patients’ Bodies as a Manufacturing Vessel to Provide Effective Tumor Killing – in vivo Editing

Synopsis

  • Utilizing Novel in vivo technologies to ensure consistent delivery despite human variability
  • Exploiting innovative gene modification technologies to edit and control  gene expression of tumor cells in the body
  • Assessing the impact of in vivo editing on producing a standardized and scaled product and improving clinical trials
  • Utilizing engineered vectors for in vivo T cell engineering and small molecules to control in vivo manufactured CAR-Ts

2:30 pm Afternoon Break & Speed Networking

Understanding the Latest Clinical Development to Supercharge Further Trials

3:00 pm Examining the Biology of Cell Therapies to Better Inform Clinical Development & Targeting of Solid Tumors

Synopsis

  • Learning from the clinical trials of heme malignancies
  • Discussing the challenges posed by different solid tumor microenvironments
  • Overcoming the efficacy barriers that exist in solid tumor indications

3:30 pm Advancing Off-The-Shelf Immunotherapy for Solid Tumors: Using Gene-Edited iNK Cells

Synopsis

  • What are the important features for product-centric, ‘off-the-shelf’ immunotherapy, and how can we create this?
  • Establishing gene-editing and manufacture systems for functionally enhanced iPSC derived iNK cells
  • Translating allogeneic products to the clinic: the development of CTH-401

4:00 pm Clinical Trial Updates for TAC Technology

  • Paul Lammers President & Chief Executive Officer, Triumvira Immunologics

Synopsis

  • Elucidating the difference between TAC technology and other cell therapies
  • Providing updates of clinical developments
  • Using clinical to data to inform the future of phase I and II trials

4:30 pm Improving Cell Therapy Clinical Development through Exploring Patient Selection and the Role of the Patient

Synopsis

  • Exploring clinical development points, such as patient selection, and patient input toward improved strategy and participation
  • Harnessing patient-centric medical communications to raise awareness and improve uptake
  • Improving patient support through inducing physician and patient care team
  • Understanding the role of the patient in issues of value and equity for patients, physicians and insurers

5:00 pm Chair’s Closing Remarks & Close of Day 2